| Autor: |
Penetar DM; Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School MA 02478, USA. dpenetar@mclean.harvard.edu, Looby AR, Su Z, Lundahl LH, Erös-Sarnyai M, McNeil JF, Lukas SE |
| Jazyk: |
angličtina |
| Zdroj: |
Human psychopharmacology [Hum Psychopharmacol] 2006 Dec; Vol. 21 (8), pp. 549-59. |
| DOI: |
10.1002/hup.810 |
| Abstrakt: |
Benztropine (Cogentin ) was evaluated for its ability to block cocaine's physiological and subjective effects in humans. In healthy, recreational users of cocaine, placebo, or benztropine (1, 2, and 4 mg orally) was given 2 hr before subjects self-administered 0.9 mg/kg of cocaine intranasally. Measurements were made for 2 hr following cocaine administration, and plasma cocaine and cocaine metabolites were assayed. Cocaine produced typical increases in heart rate and alterations in self-reports measured by visual analog scales (VAS). Benztropine alone did not produce changes on any of these measures. Responses to cocaine with and without benztropine pretreatment were similar: benztropine did not change cocaine's effects. This study of one of the tropane-ring analogs that is approved for human use suggests this compound does not alter cocaine-induced effects, but just as importantly, does not produce any adverse behavioral or physiological effects. The exact therapeutic application of benztropine as a possible adjunct treatment for cocaine abuse in humans require further exploration. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
